Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetLife, Inc. (NYSE: MET) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-supported tools to help interpret them. MetLife is a global financial services company offering insurance, annuities, employee benefits and asset management, with operations in more than 40 markets and leading positions in the United States, Asia, Latin America, Europe and the Middle East.
Investors can review current reports on Form 8-K, where MetLife discloses material events such as earnings announcements, segment reorganizations, acquisitions, reinsurance transactions and dividend declarations. Recent 8-K filings describe the designation of MetLife Investment Management (MIM) as a reportable segment, the reclassification of MetLife Holdings, the acquisition of PineBridge Investments, and a variable annuity reinsurance transaction with Talcott Resolution Life Insurance Company. Other 8-Ks address preliminary variable investment income information, preferred stock matters, and the company’s response to an unsolicited mini-tender offer.
Through this page, users can also locate quarterly and annual reporting materials referenced in MetLife’s filings, such as earnings releases, Quarterly Financial Supplements, total assets under management fact sheets and historical results supplements. These documents provide detail on segment performance across Group Benefits, Retirement and Income Solutions, regional insurance operations and MetLife Investment Management, as well as information on variable investment income and capital management.
Stock Titan’s platform enhances these filings with AI-powered summaries that explain key terms, highlight important changes and help clarify how specific disclosures may relate to MetLife’s broader business. Users can quickly identify items related to dividends, capital structure, segment changes, asset management acquisitions and risk transfer transactions without reading every line of each filing.
MetLife, Inc. filed a Form 13F Combination Report reporting holdings managed by its investment subsidiaries. The report lists 6 securities entries with a total reported market value of $11,126,208. The filing is signed by John McCallion on 11-10-2025.
MetLife, Inc. reported a change in beneficial ownership. The Board of Directors, as an entity, filed an amended Schedule 13D noting beneficial ownership of 106,549,803 shares of common stock, representing 16.17% of the class as of October 31, 2025. The Board has shared voting power over 106,549,803 shares and no sole voting or dispositive power.
The shares are held by the MetLife Policyholder Trust, originally issued 494,466,664 shares in 2000 under the demutualization plan. The Trustee votes per Board recommendations on most matters; on specified Beneficiary Consent Matters, votes are cast in proportion to beneficiary instructions. Since July 31, 2025, Trust holdings decreased from 108,242,821 to 106,549,803 due to beneficiary transactions and withdrawals under the Plan and Trust Agreement. Beneficiaries have rights to dividends and sale proceeds on their allocated shares.
MetLife, Inc. reports mixed results for the quarter and nine months ended September 30, 2025. Total revenues for the quarter were $17.4 billion, down from $18.4 billion a year earlier, and net income fell to $902 million from $1.34 billion. Diluted EPS for common shareholders declined to $1.22 from $1.81.
For the first nine months of 2025, revenues were $53.3 billion versus $52.3 billion, but net income decreased to $2.59 billion from $3.17 billion, reflecting weaker investment and derivative results. By contrast, consolidated adjusted earnings rose to $1.65 billion in the quarter from $1.44 billion, with strong contributions from Asia and Group Benefits.
Operating cash flow remained robust at $10.0 billion for the nine months. The company continued returning capital, repurchasing $2.42 billion of common stock and redeeming $988 million of preferred stock, while total assets grew to $719.7 billion and equity to $29.2 billion.
MetLife, Inc. furnished investor materials for the quarter ended September 30, 2025. The company provided an Earnings Release (Exhibit 99.1), a Quarterly Financial Supplement (Exhibit 99.2), a Total AUM Fact Sheet (Exhibit 99.3), and Supplemental Slides (Exhibit 99.4). These materials are furnished, not filed, and summarize quarterly results and assets under management.
MetLife (MET) reported an insider administrative transaction by its EVP & Chief Legal Officer. On 10/31/2025, 4,420 shares of common stock were withheld at $79.82 under transaction code F, which indicates shares withheld to cover taxes on restricted stock units.
After this transaction, the reporting person directly owned 10,452 shares.
MetLife, Inc. (MET) disclosed an insider equity transaction by its EVP & Chief Accounting Officer. On 10/31/2025, the officer acquired 11,902 shares of common stock, reported as directly owned after the transaction. A footnote indicates these shares relate to restricted stock units, each representing the right to receive one share of MetLife common stock.
This filing records an equity award event and updates the officer’s reported holdings; it does not reflect an open‑market purchase or sale.
The Vanguard Group filed Amendment No. 9 to Schedule 13G reporting beneficial ownership of 64,749,341 MetLife (MET) common shares, representing 9.73% of the class as of 09/30/2025.
Vanguard reports 0 shares with sole voting power and 3,353,980 with shared voting power. It has sole dispositive power over 59,193,894 shares and shared dispositive power over 5,555,447 shares. The filing identifies Vanguard as an investment adviser and certifies the holdings were acquired and are held in the ordinary course, not to change or influence control.
The filing notes that Vanguard’s clients have the right to receive dividends and sale proceeds related to the reported securities, and that no single other person’s interest exceeds 5%.
Rule 144 notice: A holder filed to sell 196 shares of common stock through Barclays on the NYSE. The filing lists an aggregate market value of $15,435 and an approximate sale date of 10/29/2025. Shares outstanding were 665,026,054.
The filer reports prior sales in the past three months by related accounts, including 333 shares on 10/01/2025 for gross proceeds of $27,282.69. This notice reflects a proposed secondary sale by an existing holder.
MetLife, Inc. filed a Certificate of Elimination to remove its 3.850% Fixed Rate Reset Non‑Cumulative Preferred Stock, Series G, from its charter effective upon filing. The company previously redeemed, repurchased or otherwise reacquired all Series G shares.
The filing eliminates the Series G Certificate of Designations from the Amended and Restated Certificate of Incorporation. Shares formerly designated as Series G return to authorized but unissued preferred stock, par value $0.01 per share, without designation as to series.
MetLife, Inc. (MET) non‑management director Carla A. Harris acquired 534 shares of MetLife common stock on 10/01/2025 at a reported price of $81.93 per share. After this transaction the reporting person beneficially owned 9,048 shares. The filing states these shares represent part of director retainer fees that were elected to be deferred under the MetLife Deferred Compensation Plan for Non‑Management Directors. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 10/03/2025.